RxDoctor Payments Data

Brittany Mize

Acute Care · Decatur, GANPI 1053067637

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Axonics, Inc. at 48.7% of the total. Reporting peaked in 2023 at $1,804 and has fallen 78.2% since, to $393 in 2025. Among acute care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,549in general payments, 2019–2025

Across 51 payments — averaging $69.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Boston Scientific$1K
  • Teleflex LLC$174
  • Sumitomo Pharma America, Inc.$75
  • Myriad Genetic Laboratories, Inc.$70
  • Laborie Medical Technologies Corp.$48
  • plus $282 from 13 others

What the payments were for

  • Travel & lodging$1,48942%
  • Food & beverage$2,06058%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,549 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$11,577
Medicare patients
30
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron22$15,910
Alfuzosin Hcl ErAlfuzosin Hcl67$1,307
Tamsulosin Hcl56$475
Ciprofloxacin Hcl81$329
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$95

Paid to pharmacies, not to this prescriber.

Other acute care in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →